These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 23757615

  • 1. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS, Seck TL, Golm GT, Meehan AG, Kaufman KD, Goldstein BJ.
    Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
    [Abstract] [Full Text] [Related]

  • 2. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ.
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [Abstract] [Full Text] [Related]

  • 3. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [Abstract] [Full Text] [Related]

  • 4. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [Abstract] [Full Text] [Related]

  • 5. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS.
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
    Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF.
    Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J, Meloni A, Han J.
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM.
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS, Chen Y, Golm GT, Langdon RB, Williams-Herman DE, Kaufman KD, Amatruda JM, Ferreira JC.
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ.
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group.
    Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
    [Abstract] [Full Text] [Related]

  • 15. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK, Lee SH, Shin J, Choi YH, Ahn YB, Lee BW, Rhee EJ, Min KW, Yoon KH.
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [Abstract] [Full Text] [Related]

  • 16. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M.
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V, Staels B, Morgan JD, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H.
    J Diabetes Complications; 2013 Aug; 27(2):177-83. PubMed ID: 23116881
    [Abstract] [Full Text] [Related]

  • 19. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group.
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.